Evaxion A/S

Evaxion A/S is a clinical-stage TechBio company headquartered in Hørsholm, Denmark, dedicated to revolutionizing medicine through artificial intelligence. Founded in 2008, the company's core mission is to decode the human immune system to discover and develop novel vaccines and immunotherapies for cancer and infectious diseases, leveraging its proprietary AI-Immunology™ platform.

The company's key offerings center around its advanced AI-Immunology™ platform, which comprises specialized AI modules such as PIONEER™ for personalized cancer vaccine design, EDEN™ for bacterial disease vaccine development, and RAVEN™ for viral diseases. Evaxion maintains a pipeline of product candidates, including personalized cancer immunotherapies like EVX-01 and EVX-02, which are currently in clinical development, alongside prophylactic vaccines targeting bacterial and viral infections.

Evaxion is publicly traded on NASDAQ under the ticker EVAX, having completed its IPO in 2021. Recent developments include the April 2026 promotion of Birgitte Rønø to Chief Scientific and Chief Operating Officer, and promising phase 2 trial data for its personalized cancer vaccine EVX-01, which demonstrated 86% vaccine target precision. Helen Tayton-Martin serves as the CEO.